EUR 27.0
(-0.37%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 358.08 Million EUR | -5.7% |
2022 | 379.72 Million EUR | 15.9% |
2021 | 327.62 Million EUR | -17.0% |
2020 | 394.74 Million EUR | -8.18% |
2019 | 429.89 Million EUR | -8.45% |
2018 | 469.57 Million EUR | -4.05% |
2017 | 489.39 Million EUR | 0.01% |
2016 | 489.34 Million EUR | 0.08% |
2015 | 488.97 Million EUR | -0.7% |
2014 | 492.42 Million EUR | -0.16% |
2013 | 493.21 Million EUR | 12.24% |
2012 | 439.42 Million EUR | 8.54% |
2011 | 404.85 Million EUR | -1.09% |
2010 | 409.32 Million EUR | -0.7% |
2009 | 412.2 Million EUR | 12.23% |
2008 | 367.28 Million EUR | 6.73% |
2007 | 344.13 Million EUR | 10.92% |
2006 | 310.25 Million EUR | 10.57% |
2005 | 280.6 Million EUR | 21.97% |
2004 | 230.06 Million EUR | -16.2% |
2003 | 274.54 Million EUR | 5.75% |
2002 | 259.62 Million EUR | 8.51% |
2001 | 239.25 Million EUR | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | 167.69 Million EUR | 0.0% |
2023 Q2 | 174.91 Million EUR | 0.0% |
2023 Q4 | 183.16 Million EUR | 0.0% |
2023 FY | 358.08 Million EUR | -5.7% |
2022 Q2 | 172.39 Million EUR | 0.0% |
2022 Q4 | 207.33 Million EUR | 0.0% |
2022 FY | 379.72 Million EUR | 15.9% |
2021 FY | 327.62 Million EUR | -17.0% |
2021 Q4 | 193.36 Million EUR | 0.0% |
2021 Q2 | 134.26 Million EUR | 0.0% |
2020 Q2 | 193.07 Million EUR | 0.0% |
2020 Q4 | 201.66 Million EUR | 0.0% |
2020 FY | 394.74 Million EUR | -8.18% |
2019 FY | 429.89 Million EUR | -8.45% |
2019 Q4 | 236.18 Million EUR | 0.0% |
2019 Q2 | 193.71 Million EUR | 0.0% |
2018 Q2 | 215.54 Million EUR | 0.0% |
2018 FY | 469.57 Million EUR | -4.05% |
2018 Q4 | 254.02 Million EUR | 0.0% |
2017 Q2 | 226.76 Million EUR | 0.0% |
2017 Q4 | 262.62 Million EUR | 0.0% |
2017 FY | 489.39 Million EUR | 0.01% |
2016 FY | 489.34 Million EUR | 0.08% |
2016 Q2 | 225.66 Million EUR | 0.0% |
2016 Q4 | 263.67 Million EUR | 0.0% |
2015 Q4 | 270.58 Million EUR | 0.0% |
2015 Q2 | 218.39 Million EUR | 0.0% |
2015 FY | 488.97 Million EUR | -0.7% |
2014 Q2 | 210.73 Million EUR | 0.0% |
2014 FY | 492.42 Million EUR | -0.16% |
2014 Q4 | 281.68 Million EUR | 0.0% |
2013 Q2 | 220.11 Million EUR | 0.0% |
2013 FY | 493.21 Million EUR | 12.24% |
2013 Q4 | 273.09 Million EUR | 0.0% |
2012 Q2 | 109.92 Million EUR | 0.0% |
2012 FY | 439.42 Million EUR | 8.54% |
2012 Q1 | 109.92 Million EUR | 0.0% |
2012 Q3 | 109.92 Million EUR | 0.0% |
2012 Q4 | 122.14 Million EUR | 11.11% |
2011 Q2 | 101.21 Million EUR | 0.0% |
2011 FY | 404.85 Million EUR | -1.09% |
2011 Q4 | 109.92 Million EUR | 8.61% |
2011 Q1 | 101.21 Million EUR | 0.0% |
2011 Q3 | 101.21 Million EUR | 0.0% |
2010 Q2 | 102.33 Million EUR | 0.0% |
2010 FY | 409.32 Million EUR | -0.7% |
2010 Q4 | 101.21 Million EUR | -1.09% |
2010 Q3 | 102.33 Million EUR | 0.0% |
2010 Q1 | 102.33 Million EUR | 0.0% |
2009 Q2 | 103.05 Million EUR | 0.0% |
2009 Q3 | 103.05 Million EUR | 0.0% |
2009 Q4 | 102.33 Million EUR | -0.7% |
2009 FY | 412.2 Million EUR | 12.23% |
2009 Q1 | 103.05 Million EUR | 0.0% |
2008 FY | 367.28 Million EUR | 6.73% |
2008 Q4 | 103.05 Million EUR | 12.23% |
2008 Q3 | 91.82 Million EUR | 0.0% |
2008 Q2 | 91.82 Million EUR | 0.0% |
2008 Q1 | 91.82 Million EUR | 0.0% |
2007 Q3 | 86.03 Million EUR | 0.0% |
2007 Q2 | 86.03 Million EUR | 0.0% |
2007 Q1 | 86.03 Million EUR | 0.0% |
2007 Q4 | 91.82 Million EUR | 6.73% |
2007 FY | 344.13 Million EUR | 10.92% |
2006 Q4 | 86.03 Million EUR | 10.92% |
2006 Q3 | 77.56 Million EUR | 0.0% |
2006 Q2 | 77.56 Million EUR | 0.0% |
2006 Q1 | 77.56 Million EUR | 0.0% |
2006 FY | 310.25 Million EUR | 10.57% |
2005 FY | 280.6 Million EUR | 21.97% |
2005 Q4 | 77.56 Million EUR | 10.57% |
2005 Q3 | 70.15 Million EUR | 0.0% |
2005 Q2 | 70.15 Million EUR | 0.0% |
2005 Q1 | 70.15 Million EUR | 0.0% |
2004 FY | 230.06 Million EUR | -16.2% |
2004 Q4 | 70.15 Million EUR | 21.97% |
2004 Q3 | 57.51 Million EUR | 0.0% |
2004 Q2 | 57.51 Million EUR | 0.0% |
2004 Q1 | 57.51 Million EUR | 0.0% |
2003 Q4 | 57.51 Million EUR | -16.2% |
2003 FY | 274.54 Million EUR | 5.75% |
2003 Q3 | 68.63 Million EUR | 0.0% |
2003 Q2 | 68.63 Million EUR | 0.0% |
2003 Q1 | 68.63 Million EUR | 0.0% |
2002 Q1 | 64.9 Million EUR | 0.0% |
2002 FY | 259.62 Million EUR | 8.51% |
2002 Q4 | 68.63 Million EUR | 5.75% |
2002 Q3 | 64.9 Million EUR | 0.0% |
2002 Q2 | 64.9 Million EUR | 0.0% |
2001 FY | 239.25 Million EUR | 0.0% |
2001 Q1 | 59.81 Million EUR | 0.0% |
2001 Q2 | 59.81 Million EUR | 0.0% |
2001 Q3 | 59.81 Million EUR | 0.0% |
2001 Q4 | 64.9 Million EUR | 8.51% |
2000 Q4 | 59.81 Million EUR | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Laboratorios Farmaceuticos Rovi, S.A. | 483.34 Million EUR | 25.915% |
Vetoquinol SA | 291.37 Million EUR | -22.892% |
Valneva SE | 52.83 Million EUR | -577.713% |
AB Science S.A. | 587 Thousand EUR | -60902.215% |
Nanobiotix S.A. | 42.35 Million EUR | -745.373% |
PHAXIAM Therapeutics S.A. | 1.32 Million EUR | -26904.751% |
Vivoryon Therapeutics N.V. | -3.09 Million EUR | 11669.725% |
BioSenic S.A. | 543 Thousand EUR | -65845.304% |
ABIVAX Société Anonyme | 3.91 Million EUR | -9048.774% |
Formycon AG | 23.3 Million EUR | -1436.507% |